search
Back to results

Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet (Cesamet)

Primary Purpose

Postoperative Nausea and Vomiting

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Nabilone
Placebo
Sponsored by
Unity Health Toronto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Postoperative Nausea and Vomiting

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18 or older with an American Society of Anesthesiologists (ASA) physical status of I to III who are scheduled to undergo elective surgery under general anesthesia with pre-anesthesia consultation prior to surgery.
  • Subjects must be able to swallow study medication;
  • At a risk of postoperative nausea and vomiting of at least 61% percent, according to a simplified risk score, based on the presence of at least three of the following risk factors: female sex, nonsmoker status, anticipated use of postoperative opioid and previous PONV or motion sickness.

Exclusion Criteria:

  • Subjects with clinically significant or unstable cardiac, respiratory, hepatic, renal, or other major organ system disease
  • Patients who will not be admitted to the PACU post-operatively (patients who are immediately transferred to the ICU)
  • Known sensitivity to marijuana or other cannabinoid agents
  • Psychotic illness or depression
  • Addiction to illicit substances or alcohol
  • Non-psychotic emotional disorders.
  • Pregnant or lactating
  • Subjects who suffer from chronic nausea and/or vomiting;
  • Has had treatment with any other investigational drug within 12 weeks prior to randomization
  • Subjects who, in the opinion of the investigator, would experience an unacceptable risk from administration of study drug

Sites / Locations

  • St Michael's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Cesamet (nabilone)

Placebo

Arm Description

0.5 mg capsule containing Cesamet (single dose) given preoperatively

identical capsule containing placebo (single dose) given preoperatively

Outcomes

Primary Outcome Measures

Incidence of postoperative nausea and/or vomiting

Secondary Outcome Measures

Number of antiemetic rescue medications given postoperatively.

Full Information

First Posted
March 3, 2014
Last Updated
December 1, 2015
Sponsor
Unity Health Toronto
search

1. Study Identification

Unique Protocol Identification Number
NCT02115529
Brief Title
Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet
Acronym
Cesamet
Official Title
A Randomized Controlled Trial of Cesamet(R) (Nabilone) for the Prevention of Postoperative Nausea and Vomiting in Elective Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
April 2014 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
November 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Unity Health Toronto

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Untreated, one third of patients undergoing general anesthesia will have postoperative nausea, vomiting, or both. Patients often rate postoperative nausea and vomiting (PONV) as worse than postoperative pain. PONV increases the risk of aspiration and has been associated with suture dehiscence, esophageal rupture, subcutaneous emphysema, and bilateral pneumothoraxes. PONV frequently delays discharge, and is the leading cause of unexpected hospital admission after planned ambulatory surgery. Nabilone (Cesamet®) is a synthetic cannabinoid developed in the 1970s which is a potent CB1 agonist. The use of nabilone in preventing nausea and vomiting in patients receiving chemotherapy has been thoroughly investigated. Results from clinical studies demonstrated the efficacy, safety, and tolerability of Cesamet in this population. There has been success in the past translating treatments for chemotherapy-induced nausea and vomiting (ie. 5-HT receptor agonists including Ondansetron and Granisetron) to use in the perioperative environment. Only one RCT has studied the use of nabilone for the reduction of PONV. Published in 1995, this study compared the administration of either Cesamet 2 mg or metoclopramide 10 mg given 90 minutes before the operation in patients scheduled for elective hysterectomy in 60 women. This study failed to show any significant difference between groups. There are several limitations to this study including a poorly optimized dosing regimen, a small sample size, and a comparison group lacking clinical generalizability. This study will investigate the use Cesamet vs Placebo, in addition to the regular antiemetic treatment which patients receive at the discretion of the managing anesthesiologist, for the prevention of PONV. The study group will include patients undergoing general anesthesia for elective ambulatory surgery with at least 3 risk factors (>60% risk) for the development of PONV.
Detailed Description
See above

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Nausea and Vomiting

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
331 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cesamet (nabilone)
Arm Type
Active Comparator
Arm Description
0.5 mg capsule containing Cesamet (single dose) given preoperatively
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
identical capsule containing placebo (single dose) given preoperatively
Intervention Type
Drug
Intervention Name(s)
Nabilone
Other Intervention Name(s)
Cesamet
Intervention Description
Nabilone (0.5 mg) or placebo given preoperatively
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively
Primary Outcome Measure Information:
Title
Incidence of postoperative nausea and/or vomiting
Time Frame
Prior to discharge from postanesthesia care unit, an expected average of two hours
Secondary Outcome Measure Information:
Title
Number of antiemetic rescue medications given postoperatively.
Time Frame
Prior to discharge from postanesthesia care unit, an expected average of two hours
Other Pre-specified Outcome Measures:
Title
Standardized score of nausea and/or vomiting severity if PONV occurs.
Time Frame
Prior to discharge from postanesthesia care unit, an expected average of two hours
Title
Pain score during the immediate post-operative period.
Time Frame
Prior to discharge from postanesthesia care unit, an expected average of two hours
Title
Use of intraoperative and postoperative opioids
Time Frame
Prior to discharge from postanesthesia care unit, an expected average of two hours
Title
Rates of known side effects.
Description
Nabilone side effects include: drowsiness, vertigo, psychological high, dry mouth, depression, blurred vision, sensation disturbance, anorexia, headache, euphoria, and hallucinations (based on patient self-reporting).
Time Frame
Prior to discharge from postanesthesia care unit, an expected average of two hours
Title
Time to discharge from the PACU.
Time Frame
Prior to discharge from postanesthesia care unit, an expected average of two hours
Title
Rates of admission due to PONV
Time Frame
Prior to discharge from postanesthesia care unit, an expected average of two hours
Title
Antiemetics given prophylactically by the anesthesiologist.
Time Frame
Until discharge from postanesthesia care unit, an expected average of two hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 or older with an American Society of Anesthesiologists (ASA) physical status of I to III who are scheduled to undergo elective surgery under general anesthesia with pre-anesthesia consultation prior to surgery. Subjects must be able to swallow study medication; At a risk of postoperative nausea and vomiting of at least 61% percent, according to a simplified risk score, based on the presence of at least three of the following risk factors: female sex, nonsmoker status, anticipated use of postoperative opioid and previous PONV or motion sickness. Exclusion Criteria: Subjects with clinically significant or unstable cardiac, respiratory, hepatic, renal, or other major organ system disease Patients who will not be admitted to the PACU post-operatively (patients who are immediately transferred to the ICU) Known sensitivity to marijuana or other cannabinoid agents Psychotic illness or depression Addiction to illicit substances or alcohol Non-psychotic emotional disorders. Pregnant or lactating Subjects who suffer from chronic nausea and/or vomiting; Has had treatment with any other investigational drug within 12 weeks prior to randomization Subjects who, in the opinion of the investigator, would experience an unacceptable risk from administration of study drug
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aaron P Hong, MD, FRCPC
Organizational Affiliation
St Michael's Hospital, University of Toronto
Official's Role
Principal Investigator
Facility Information:
Facility Name
St Michael's Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B 1W8
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
15064261
Citation
Habib AS, Gan TJ. Evidence-based management of postoperative nausea and vomiting: a review. Can J Anaesth. 2004 Apr;51(4):326-41. doi: 10.1007/BF03018236.
Results Reference
background
PubMed Identifier
22169965
Citation
Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012 Apr;41(2):183-90. doi: 10.1007/s12020-011-9580-0. Epub 2011 Dec 15.
Results Reference
background
PubMed Identifier
20166927
Citation
Pertwee RG. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem. 2010;17(14):1360-81. doi: 10.2174/092986710790980050.
Results Reference
background
PubMed Identifier
18728826
Citation
Ware MA, Daeninck P, Maida V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag. 2008 Feb;4(1):99-107. doi: 10.2147/tcrm.s1132.
Results Reference
background
PubMed Identifier
20844345
Citation
Hsu ES. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. Am J Ther. 2010 Sep-Oct;17(5):476-86. doi: 10.1097/MJT.0b013e3181ea7821.
Results Reference
background
PubMed Identifier
7917745
Citation
Lewis IH, Campbell DN, Barrowcliffe MP. Effect of nabilone on nausea and vomiting after total abdominal hysterectomy. Br J Anaesth. 1994 Aug;73(2):244-6. doi: 10.1093/bja/73.2.244.
Results Reference
background
PubMed Identifier
9165963
Citation
Koivuranta M, Laara E, Snare L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia. 1997 May;52(5):443-9. doi: 10.1111/j.1365-2044.1997.117-az0113.x.
Results Reference
background
PubMed Identifier
11886298
Citation
Gan TJ. Postoperative nausea and vomiting--can it be eliminated? JAMA. 2002 Mar 13;287(10):1233-6. doi: 10.1001/jama.287.10.1233. No abstract available.
Results Reference
background
PubMed Identifier
15190136
Citation
Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, Zernak C, Danner K, Jokela R, Pocock SJ, Trenkler S, Kredel M, Biedler A, Sessler DI, Roewer N; IMPACT Investigators. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004 Jun 10;350(24):2441-51. doi: 10.1056/NEJMoa032196.
Results Reference
background
PubMed Identifier
8123411
Citation
Bremner WG, Kumar CM. Delayed surgical emphysema, pneumomediastinum and bilateral pneumothoraces after postoperative vomiting. Br J Anaesth. 1993 Aug;71(2):296-7. doi: 10.1093/bja/71.2.296.
Results Reference
background
PubMed Identifier
9717590
Citation
Fortier J, Chung F, Su J. Unanticipated admission after ambulatory surgery--a prospective study. Can J Anaesth. 1998 Jul;45(7):612-9. doi: 10.1007/BF03012088.
Results Reference
background
PubMed Identifier
10475299
Citation
Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg. 1999 Sep;89(3):652-8. doi: 10.1097/00000539-199909000-00022.
Results Reference
background
Citation
Product monograph, Nabilone (Nabilone), submission control no: 124406, Valeant Canada Limitée/Limited, March 17, 2009
Results Reference
background
PubMed Identifier
28160217
Citation
Levin DN, Dulberg Z, Chan AW, Hare GM, Mazer CD, Hong A. A randomized-controlled trial of nabilone for the prevention of acute postoperative nausea and vomiting in elective surgery. Can J Anaesth. 2017 Apr;64(4):385-395. doi: 10.1007/s12630-017-0814-3. Epub 2017 Feb 3.
Results Reference
derived

Learn more about this trial

Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet

We'll reach out to this number within 24 hrs